Delving into the Latest Updates on Beijing Yuance Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Endocrinology and Metabolic Disease

Interleukins

Interferons

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1
Infectious Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Interferons	1
Interleukins	1

Top 5 Target	Count

IFNAR(Interferon alpha/beta receptor)	1
IL-2R(Interleukin-2 receptor)	1

A review with 26 referencesThe topic discussed include: (1) the summary of interferon-γ (type II interferon) and its clin. application for treating chronic granulomatous disease (CGD), severe malignant osteosclerosis, congenital pulmonary fibrosis and rheumatoid arthritis etc.; and (2) the summary of interferon-γ (type III interferon).

100 Deals associated with Beijing Yuance Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Yuance Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human interleukin-2(Beijing Yuance Pharmaceutical Co Ltd) ( IL-2R )	Neoplasms More	Approved
Recombinant human interferon α2b(Beijing Yuance Pharmaceutical Co Ltd) ( IFNAR )	Hairy Cell Leukemia More	Approved